Why the study?
CMD is a multifactorial disease that affects patients with autoimmune rheumatic and endocrine/metabolic disorders, creating an intersection between Cardiology, Rheumatology, and Endocrinology.
Key points are not available for this paper at this time.
Design
Review
Advanced imaging modalities like CMR should be utilized to assess coronary microvascular disease across cardiology, rheumatology, and endocrinology patients.
CMD is a multifactorial disease leading to myocardial ischemia/fibrosis alone or in combination with epicardial coronary artery disease. Endothelial dysfunction/vasospasm, systemic inflammation, and/or neuroendocrine activation may act as causative factors and bring Cardiology, Rheumatology and Endocrinology together. Currently, the application of advanced imaging modalities, and specifically CMR, allows reliable assessment of the extent and severity of CMD. These measurements should not be limited to "pure cardiac patients", as it is known that CMD affects the majority of patients with autoimmune rheumatic and endocrine/metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Markousis‐Mavrogenis et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: